<DOC>
	<DOCNO>NCT00595413</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy atacicept compare placebo treatment sign symptom subject population active rheumatoid arthritis ( RA ) , inadequate response methotrexate ( MTX ) previous exposure anti-tumor necrosis factor alpha ( anti-TNFalpha ) therapy .</brief_summary>
	<brief_title>Atacicept Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis ( AUGUST II )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male female subject great equal ( &gt; = ) 18 year age time inform consent RA satisfy American College Rheumatology ( ACR ) criteria disease history least 6 month Subjects must active disease , define &gt; =8 swollen joint ( 66 ) , &gt; =8 tender joint ( 68 ) CRP &gt; =10 milligram per liter ( mg/L ) and/or erythrocyte sedimentation rate ( ESR ) &gt; =28 millimeter per hour ( mm/hr ) , despite treatment MTX dose &gt; =15 milligram per week ( mg/week ) great ( &gt; ) 3 month Other protocoldefined inclusion criterion could apply Inflammatory joint disease RA Previous concurrent treatment approve investigational biological compound RA , include restrict antiTNFalpha agent , rituximab , abatacept , tocilizumab , interleukin1 receptor antagonist ( IL1Ra ) belimumab Treatment diseasemodifying antirheumatic drug ( DMARDs ) MTX Participation interventional clinical trial within 1 month study Day 1 MTX dose &gt; 25 mg/week , prednisone dose &gt; 10 mg/day ( equivalent ) , change steroid nonsteroidal antiinflammatory drug ( NSAID ) dose regimen within 28 day study Day 1 Immunization live vaccine immunoglobulin ( Ig ) treatment within 28 day study Day 1 need treatment study ( include followup ) Any history presence active latent tuberculosis , major infection require hospitalization intravenous antiinfectives within 28 day study Day 1 Other major concurrent illness organ dysfunction specify protocol Serum IgG 6 gram per liter ( g/L ) Known hypersensitivity atacicept component formulate atacicept Other protocoldefined exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Atacicept</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Humira®</keyword>
</DOC>